Castiglione A, Ciccone G, Chirillo F, Cecconi M, Del Ponte S, Moreo A, Faggiano P, Cialfi A, Rinaldi M, Cecchi E

Similar documents
Endocarditis: Medical vs. Surgical Treatment. Nabin K. Shrestha, MD, MPH Infectious Diseases

Andrea Ungar, MD, PhD, FESC

Indications chirurgicales dans l endocardite infectieuse

The Ross Procedure: Outcomes at 20 Years

CAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL?

Riflessioni sui risultati prodotti, sviluppi futuri e nuove proposte

Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection

Supplement materials:

Incidence of Postoperative Atrial Fibrillation after minimally invasive mitral valve surgery

Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer

La metodologia della ricerca clinica: aspetti salienti per l oncologo

Race Original cohort Clean cohort HR 95%CI P HR 95%CI P. <8.5 White Black

Criteri di selezione dei pazienti Criteri restrittivi vs.

SUPPLEMENTAL MATERIALS

Firenze, 21/07/2017. Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia Università Federico II Naples, Italy

Evidence-Based in Clinical Behavioral Infectivology

The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)

La terapia alla luce delle linee guida: oltre i beta-bloccanti e gli ace-inibitori

16/06/2014. Introduzione I motivi di uno studio visti da un clinico. Riccardo Pistelli Università Cattolica - Roma

FRAGILITÀ, DISABILITÀ E MALATTIE NELLO STUDIO PRO.V.A. Enzo Manzato (Padova)

Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies

Update: Chronic Lymphocytic Leukemia

Supplementary Online Content

Pitfalls to Avoid in Observational Studies in the ICU

Choosing the right study design

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

11 questions to help you make sense of a case control study

Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women with Type 2 Diabetes.

Modifiers of the clinical course of infective endocarditis

Cardiolucca Heart Celebration. Seconda generazione delle valvole e miglioramento degli outcome nel trattamento percutaneo della stenosi aortica

ASCO GI 2018: Rectal Cancer Take home messages

Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database

Identifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas

Incidence, Predictors, and Outcomes of Prosthesis-Patient Mismatch in 62,125 TAVR Patients. An STS/ACC TVT Registry Report

Person-years; number of study participants (number of cases) HR (95% CI) P for trend

Should I use statins?

CRITICAL APPRAISAL SKILLS PROGRAMME Making sense of evidence about clinical effectiveness. 11 questions to help you make sense of case control study

Infections Amenable to OPAT. (Nabin Shrestha + Ajay Mathur)

Declaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018

Pre-diagnostic cruciferous vegetables intake and lung cancer survival among Chinese women

Non-Compliance with Guidelines: Motivations and Consequences in a case study. The ischemic stroke management

Contempo GIMSI Cosa cambia alla luce della letteratura in tema di terapia farmacologica

Maurizio D Amico M.D.

Positive Bone Marrow Biopsy is Associated with a Decreased Disease-Free Survival in Patients with Operable Breast Cancer

Rayzel Shulman MD, PhD CAHSPR May 10, 2016

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?

Arbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia

Il punto di vista della SIGG

Long-term results (22 years) of the Ross Operation a single institutional experience

Template 1 for summarising studies addressing prognostic questions

Introduction ORIGINAL RESEARCH

Le nuove tossicità in oncologia: come cambia l informazione al paziente

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva

MY CONFLICTS OF INTEREST ARE

Staging and prognostic systems: beyond BCLC?

Declaration of Conflict of Interest. No potential conflict of interest to disclose with regard to the topics of this presentations.

The National Heart Failure Audit 2010/2011

EPO e Ferro in Emodialisi: Il PBM al suo esordio. Lucia Del Vecchio. Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco

Arteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante

Questionnaire information Name of the questionnaire Questionario per l'informatore [Informant questionnaire]

Pr Fadi FARHAT Service de Chirurgie Cardiovasculaire Adulte et Transplantation Hôpital Louis Pradel, Bron, FRANCE. NOM Intitulé du topo Date.

Endocardite infectieuse

Catheter-based mitral valve repair MitraClip System

Colonoscopy overuse in colorectal cancer screening in Argentina. Ignacio Ricci

Substance Use Among Potential Kidney Transplant Candidates and its Impact on Access to Kidney Transplantation: A Canadian Cohort Study

Cover Page. The handle holds various files of this Leiden University dissertation.

A systems biology study to tailored treatment in chronic heart failure Ouwerkerk, W.

The Linked SEER-Medicare Data and Cancer Effectiveness Research

Hospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia

Le target therapy nei Tumori Neuroendocrini

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW

SOF: Summary of Findings tables. Negrar, 7 aprile 2018

DECLARATION OF CONFLICT OF INTEREST. None declared

Supplementary Online Content

COPD and environmental risk factors other than smoking. 14. Summary

Disclosures. Investigator-initiated study funded by Astellas

INTERPRETATION OF STUDY FINDINGS: PART I. Julie E. Buring, ScD Harvard School of Public Health Boston, MA

Zhao Y Y et al. Ann Intern Med 2012;156:

Large RCT s of CRT 2002 to present

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Percutaneous Repair for MR:

FIBRILLAZIONE ATRIALE. Mauro Zennaro

Advances in Cardiac Arrhythmias and Great innovations in Cardiology Turin October 2016

Challenges in design and analysis of large register-based epidemiological studies

Finland and Sweden and UK GP-HOSP datasets

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome

La salute dell osso nelle pazienti in trattamento adiuvante. Airoldi Mario - S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino

Giorgio VESCOVO MD PhD London

Transfusion for the sickest ICU patients: Are there unanswered questions?

A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Helen Mari Parsons

MODEL SELECTION STRATEGIES. Tony Panzarella

Results of Transfemoral Transcatheter Aortic Valve Implantation

The Irish Renal Transplant Registry: recipient demographics and outcomes / K.A. Abraham... [et al.]

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice

had non-continuous enrolment in Medicare Part A or Part B during the year following initial admission;

Author's response to reviews

Ruolo della riabilitazione nel paziente anziano coronaropatico

Health technology Management, by cardiologists or generalists, of patients with congestive heart failure.

Zilver PTX Drug-Eluting Stent Mortality Analysis

Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis

Transcription:

Timing della chirurgia e mortalità in pazienti affetti da endocardite infettiva su valvola aortica o mitralica: uno studio multicentrico (Registro Italiano delle Endocarditi infettive RIEI) Castiglione A, Ciccone G, Chirillo F, Cecconi M, Del Ponte S, Moreo A, Faggiano P, Cialfi A, Rinaldi M, Cecchi E

Background IE is relatively rare disease (4 to 7 cases per 100,000), with potentially serious complications (heart damage, embolic events) Diagnostic delay and treatment uncertainty may increase mortality In addition to antimicrobial therapy, heart surgery was associated to reduced mortality in several studies, but available evidence is of low quality (mainly observational studies at high risk of bias and only one small RCT). Guidelines recommend early surgery in selected cases, but there is no clear definition of optimal timing

Date of download: 10/29/2015 Copyright 2015 McGraw-Hill Education. All rights reserved.

Treatment of infective endocarditis (IE)

Treatment of infective endocarditis (IE) * Early surgery: during initial hospitalization before completion of a full therapeutic course of antibiotics

Study aims To compare the overall survival between two treatment strategies in patients with left side IE: early surgery late surgery/medical therapy To assess the impact on the results of: indication bias immortal time bias

Methods (1) RIEI: 17 Italian centers from July 2007 to December 2010 collected data: socio-demographic and clinical data at IE diagnosis medical and surgical treatments complications and vital status during the 12 months after diagnosis Inclusion/esclusion criteria for the present study: only patients with a new diagnosis of left side IE excluded patients with cardiac devices

Methods (2) Estimation of the surgery effect on survival, including surgery in multivariable Cox models in 3 different ways: surgery at any time; early surgery (<= 14 days from IE diagnosis); early surgery as time-dependent variable. Hazard Ratios adjusted for potential confounders (factors associated to early surgery) selected with a logistic model: Age, sex, comorbidity, severity of IE, acute cardiac complications, causative microorganism, suspected etiology, involved valve

Results Flow Chart

Cumulative incidence Results IE cumulative incidence of surgery 1.00 0.80 0.60 0.40 0.20 0.00 0 1 2 3 4 5 6 7 8 9 10 11 12 Time from IE evidence (months) Number at risk 502 142 134 130 109

Results Surgery effects on OS HR (95% CI) Surgery at any time (not time-dependent) 0.44 (0.28;0.67) 0.41 (0.25;0.70) Early surgery (not time-dependent) 0.68 (0.42;1.09) 0.69 (0.40;1.18) Early surgery (time-dependent) 0.61 (0.18;1.99) 0.64 (0.19;2.15) 0.2 0.3 0.5 1.0 2.0 3.0 HR

Results Surgery effects on OS HR (95% CI) Surgery at any time (not time-dependent) 0.44 (0.28;0.67) 0.41 (0.25;0.70) Early surgery (not time-dependent) 0.68 (0.42;1.09) 0.69 (0.40;1.18) Early surgery (time-dependent) 0.61 (0.18;1.99) 0.64 (0.19;2.15) 0.2 0.3 0.5 1.0 2.0 3.0 HR

Results Surgery effects on OS HR (95% CI) Surgery at any time (not time-dependent) 0.44 (0.28;0.67) 0.41 (0.25;0.70) Early surgery (not time-dependent) 0.68 (0.42;1.09) 0.69 (0.40;1.18) Early surgery (time-dependent) 0.61 (0.18;1.99) 0.64 (0.19;2.15) 0.2 0.3 0.5 1.0 2.0 3.0 HR

Results Surgery effects on OS HR (95% CI) Surgery at any time (not time-dependent) 0.44 (0.28;0.67) 0.41 (0.25;0.70) Early surgery (not time-dependent) 0.68 (0.42;1.09) 0.69 (0.40;1.18) Early surgery (time-dependent) 0.61 (0.18;1.99) 0.64 (0.19;2.15) 0.2 0.3 0.5 1.0 2.0 3.0 HR

Conclusions Surgery seems beneficial in these patients, but its effect becomes weaker considering only early surgery, and less precise when analysed as a time dependent variable No evidence of confounding by indication Need of high quality confirmation studies EARLY is a large, pragmatic randomized trial, aiming to confirm a positive balance of benefits vs risks and costs of an early (< 72 h) surgical treatment

Tutti gli autori dichiarano assenza di conflitto di interessi

Anna Castiglione anna.castiglione@cpo.it Grazie per l attenzione!